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Poster Session I S253The experimental group will be given the WeeFIM upon admis-
sion for their allogeneic transplant and every six months thereafter,
unless they receive a diagnosis of GvHD, at which time they will
be evaluated on a bi-monthly basis. The control group will complete
the WeeFIM at their one-year post BMT (or at their next visit if
past one year).
The outcomes we anticipate achieving include: 1. Demonstrating
that range of motion assessment is a reliable indicator for early iden-
tification of skin and joint GvHD; 2. Identifying a positive relation-
ship between early intervention of GvHD and improved functional
outcomes for recipients of allogeneic BMT.256
SEVERE AND FATAL VOD FOLLOWING HEMATOPOETIC STEM CELL
TRANSPLANTATION IN TWO CHILDREN WITH SINGLE KIDNEYS
Ehlert, K., Groll, A.H., Froehlich, B., Juergens, H. University Childrens
Hospital, Muenster, Germany
Introduction: The occurrence of VOD in pediatric oncology and
HSCT has been associated with several risk factors. Impaired renal
function is frequently observed in VOD, spanning from electrolyte
disturbances and fluid retention to acute renal failure. VOD associ-
ated multi organ failure has a poor outcome.We report on two chil-
dren, 5 and 6 years old, who developed severe (1) and fatal (1) VOD,
both with a single kidney at the time of autologous HSCT for treat-
ment of stage IV neuroblastoma (NB).
Patients: Patient 1 had congenital aplasia of his right kidney. He
was diagnosed with NB in 10/2007 being treated according to
protocol NB 2004 which includes high dose chemotherapy with
melphalan, etoposide and carboplatin (MEC). There was no evi-
dence of renal impairment in previous chemotherapy courses; s-
creatinine, Ccr and urinanalysis were unremarkable. Severe VOD
peaked on day +31 of autologous HSCT with large ascites, pleu-
ral effusions and bilirubin levels of 47.3 mg/dl but with a com-
plete resolution by day +100. Patient 2 had undergone
chemotherapy, left nephrectomy and irradiation in 2007 for
treatment of wrongly diagnosed nephroblastoma in a different
country. She was correctly diagnosed with NB in 3/2008 and
treated according to protocol NB 2004. In the girl’s pre-trans-
plant evaluation, there was evidence of mild tubular renal impair-
ment, CTC grade 1; Ccr and urinanalysis proved normal.
Following autologous HSCT after MEC high dose chemother-
apy, she developed hepatic (CTC grade 3) and renal dysfunction
(CTC grade 3). Early respiratory deterioration on day +2 re-
quired mechanical ventilation and blood pressure support. She
was diagnosed with pulmonary VOD on day +34 by lung biopsy
and died on day +72. Both children had received defibrotide on
an interventional basis.
Discussion: Severity of VODwas surprising in these two children as
none had displayed any risk factors in their pre-transplant evalua-
tions. Melphalan, known for its potential to cause VOD, is fre-
quently used in pediatric high dose protocols; however, severe or
fatal courses of VOD are rarely observed. Dose reduction of melpha-
lan is recommended in renal insufficiency as its clearance may be re-
duced. Although both children had no measurable renal impairment
before high dose chemotherapy, the simultaneous use of melphalan
and carboplatin, a known nephrotoxic drug, may adversely affect
melphalan clearance in patients with a single kidney thus exposing
them to a higher risk for developing severe VOD.257
MEDICAL MANAGEMENT OF SICKLE CELL DISEASE
Vichinsky, E.P. Children’s Hospital & Research Center, Oakland, CA
Improved therapy has dramatically changed the prognosis of sickle
cell disease. Once a fatal pediatric illness, it is now a chronic adult
disease characterized by poor quality of life with end organ failure
and acute intermittent medical emergencies. Identification of high
risk patients, preventative therapies and optimal management of
complications can minimize the morbidity of sickle cell disease and
alter its progressive decline.Annual screening with transcranial Doppler enables selective
chronic transfusions to be implemented that successfully prevent
CNS injury. Early detection of asthma, pulmonary hypertension,
and hypoxia is important for improved outcomes. Acute chest syn-
drome, the most common cause of mortality, can often be pre-
vented or minimized. Renal failure may be prevented by early
treatment of proteinuria with ACE inhibitors. Avascular necrosis
of the hip may affect up to 40% of patients; early detection and
treatment with decompression coring procedures and aggressive
physical therapy may prevent or slow progression to major sur-
gery. Priapism, a morbid, often under-reported complication re-
quiring surgery, may be prevented by alpha/beta adrenergic
agonists, gonadotropin releasing hormone, and phosphodiesterase
inhibitors. Pain management in sickle cell disease remains inade-
quate, but may be improved by the day hospital model, avoidance
of hyperanalgesia syndrome, and effective use of opioids. Nutri-
tional deficiencies are common and correctable, and can improve
bone density and general health.
Transfusion therapy has seen major advances and is used in over
90% of patients by adulthood. Phenotypically matched units, access
to cytopheresis and availability of oral iron chelators have resulted in
lower alloimmunization rates and decreased iron overload. Hy-
droxyurea has globally altered the morbidity of sickle cell disease.
New hemoglobin F modulating drugs such as decitabine and short
chain fatty acids may further improve outcomes. Emerging therapies
resulting from an expanded understanding of the pathophysiology of
sickle cell disease are promising and have entered clinical trials; these
include statins, pan-selectin inhibitors, anti-coagulants, glutamine,
and nitric oxidemodifying therapies.While gene therapy has entered
Phase I trials, stem cell transplant remains the only available cure for
this disease.258
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Patients with severe aplastic anemia (SAA) unresponsive to immu-
nosuppressive therapy (IST) require hematopoietic cell transplanta-
tion (HCT) for long-term survival. We conducted an IRB-approved
pilot study using parental donors for patients failing IST and without
an acceptable matched related or unrelated donor. The preparative
regimen consisted of OKT3 (ascending to 0.1 mg/kg/day and then
descending doses), fludarabine (160 mg/m2), thiotepa (10 mg/kg),
melphalan (120 mg/m2), and rituximab (375 mg/m2). Participants
received fresh, GM-CSF and G-CSF mobilized, CD3 depleted, pe-
ripheral blood stem cell grafts processed on the CliniMACS system;
a fixed dose of 1  105 CD3+ T-cells/kg was infused. Graft-versus-
host disease (GVHD) prophylaxis was with mycophenolate mofetil.
G-CSF was started on day +6. The primary objective was safety at
day + 100. Secondary objectives were degree of donor T-cell chime-
rism and rate of acute and chronicGVHD.Two recipients, ages 15.7
and 16.5 years, were enrolled on the study in December 2006 and
June 2007. Grafts contained 9.4-14.1 106 CD34+ cells/kg.Myeloid
engraftment occurred on days +9 and +10; platelet engraftment was
on days +16 and +18. Length of initial hospitalization was 27 and 28
days. No NCI grade 4 toxicity was observed; NCI grade 3 toxicities
included cellulitis, fever with and without neutropenia, Staphylococ-
cus aureus bacteremia, methemoglobinemia, and pancreatitis. Nei-
ther required donor lymphocytes nor stem cell boosts. Maximum
grade 2 liver and grade 1 skin acute GVHD was observed. Limited
chronic GVHD occurred: one in skin and liver, the other only in
liver. At the time of last follow-up on days +571 and +756, both par-
ticipants had 100% donor T-cell chimerism, were without signs of
SAA, and had performance scores of 100. One remains on IST for
slowly resolving skin GVHD. Overall, HCT using a reduced inten-
sity preparative regimen and an extensively T cell-depleted parental
graft is safe and results in manageable toxicities and stable engraft-
ment for recipients with SAA.
